The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | TP53-mutated myeloid malignancies: multi-hit vs single-hit disease and transplant implications
Talha Badar, MD, Mayo Clinic, Rochester, MN, discusses the distinction between ‘multi-hit’ and ‘single-hit’ disease in TP53-mutated myeloid malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), highlighting how the relevance of these mutations evolves as disease progresses. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
